FIELD: biotechnology.
SUBSTANCE: invention relates to a fusion protein SIRPα-4-1BBL, containing at its N-end amino acid sequence of signal regulatory protein α(SIRPα), and on its C-end amino acid sequence of 4-1BB ligand (4-1BBL), method of its production, as well as to a kit containing it. Also disclosed is a polynucleotide coding said protein, as well as a cell and a vector containing said protein.
EFFECT: invention is effective for treating cancer expressing CD47.
22 cl, 38 dwg, 6 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED PROTEIN SIRPΑ-4-1BBL AND METHODS OF USING SAME | 2018 |
|
RU2769769C2 |
| CHIMERIC PROTEINS BASED ON TIGIT AND LIGHT | 2018 |
|
RU2775490C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
